Bodor JN et al. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020;126(2):260-70. Abstract
Bonanno L et al. Clinical impact of plasma and tissue next-generation sequencing in advanced non-small cell lung cancer: A real-world experience. The Oncologist 2020;[Online ahead of print]. Abstract
Chang S et al. Current status and future perspectives of liquid biopsy in non-small cell lung cancer. J Pathol Transl Med 2020;54(3):204-12. Abstract
Esagian SM et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: A comprehensive systematic review. J Cancer Res Clin Oncol 2020;146(8):2051-66. Abstract
Kneuertz PJ et al. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma. Lung Cancer 2020;143:60-6. Abstract
Mack PC et al. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Cancer 2020;126(14):3219-28. Abstract
Makarem M, Leighl NB. Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach? Cancer 2020;126(14):3176-80. Abstract
Marmarelis ME, Langer CJ. Treatment of patients with non-small-cell lung cancer harboring rare oncogenic mutations. Clin Lung Cancer 2020;21(5):395-406. Abstract
Rajurkar S et al. Non-small cell lung cancer from genomics to therapeutics: A framework for community practice integration to arrive at personalized therapy strategies. J Clin Med 2020;9(6):E1870. Abstract
Rossi G et al. Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient. Cancers (Basel) 2020;12(5):1125. Abstract
Salgia R et al. Evaluation of omics-based strategies for the management of advanced lung cancer. JCO Oncol Pract 2020;[Online ahead of print]. Abstract
Sands JM et al. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer 2020;140:35-41. Abstract
Sears CR, Mazzone PJ. Biomarkers in lung cancer. Clin Chest Med 2020;41(1):115-27. Abstract
Sholl LM et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: A perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 2020;[Online ahead of print]. Abstract
Taniguchi H et al. Targeted therapies and biomarkers in small cell lung cancer. Front Oncol 2020;10:741. Abstract